Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement

Haematologica

Volumn 98, Issue 10, 2013, Pages 1593-1599

  Dinner, Shira ^a   Witteles, Wesley ^b   Afghahi, Anosheh ^a   Witteles, Ronald ^a   Arai, Sally ^a   Lafayette, Richard ^a   Schrier, Stanley L ^a   Liedtke, Michaela ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIURETIC AGENT; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; SYNDECAN 1; WARFARIN;

ADULT; AGED; AMYLOIDOSIS; ANEMIA; ANOREXIA; ANXIETY DISORDER; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONFUSION; CONSTIPATION; CREATININE CLEARANCE; CYTOPENIA; DEATH; DEPRESSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECCHYMOSIS; ELECTROCORTICOGRAPHY; FAINTNESS; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ARREST; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPONATREMIA; HYPOTENSION; IMMUNOHISTOCHEMISTRY; INFECTION; INSOMNIA; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PILOT STUDY; RASH; SEIZURE; THROMBOCYTOPENIA; VOMITING;

AGED; AGED, 80 AND OVER; AMYLOIDOSIS; COHORT STUDIES; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HEART DISEASES; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MELPHALAN; MIDDLE AGED; PILOT PROJECTS; SURVIVAL RATE; THALIDOMIDE;

EID: 84884933036     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.084574     Document Type: Article

References (35)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003; 349(6):583-96.
2. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone and melphalan, prednisone and colchicine. N Engl J Med. 1997;336(17):1202-7.
3. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic lightchain (AL) amyloidosis. Leukemia. 2012; 26(11):2317-25.
4. Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicines versus colchicine only. Am J Med. 1996;100(3):290-8.
5. Palladini G, Perfetti V, Obici L, Caccialanza R, Semio A, Adami F, et al. Association of melphalan and high-dose dexamethasone is effective and well-tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103(8):2936-8.
6. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outocome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007; 110(10):3561-3.
7. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357(11):1083-93.
8. Dispenzieri A, Lacy MQ, Rajkumar SV, Geyer SM, Witzig TE, Fonesca R, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid. 2003;10(4):257-61.
9. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Wakins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109(2):457-64.
10. Bartlett JB, Dredge K, Dallies AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4(4):314-22.
11. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007; 109(2):465-70.
12. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109(2):492-6.
13. Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkin PN, Perfetti V, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031-7.
14. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Blade J, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011;118(4): 865-73.
15. Lamm W, Willenbacher W, Lang A, Zojer N, Muldur E, Ludwig H, et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol. 2011;90(2):201-6.
16. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet. 2006;367(9513):825-31.
17. Facon T, Mary J, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reducedintensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209-18.
18. Palumbo A, Falco R, Corradini P, Falcone A, Di Raimondo F, Giuliani N, et al. Melphalan, prednisone and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Onc. 2007; 25(28):4459-65.
19. Kumar SK, Lacy MQ, Hayman SR, Stewart K, Buadi FK, Allred J, et al. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol. 2011;86(8):640-5.
20. Sanchorawala V, Patel J, Sloan M, Shelton A, Zeldis J, Seldin D. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica. 2013;98(5):789-92
21. Moreau P, Jaccard A, Benboubker L, Royer B, Leleu X, Bridoux F, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly-diagnosed AL amyloidosis: a multicenter phase 1/2 dose escalation study. Blood. 2010; 116(23):4777-82.
22. Kumar SK, Hayman S, Buadi F, Roy V, Lacy M, Gert M, et al. Lenalidomide, cyclophosphamide, and dexamethasone for lighchain amyloidosis: long-term results from a phase 2 trial. Blood. 2012;119(21):4860-7.
23. Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I, et al. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone in AL-amyloidosis. Blood. 2012;119(23):5384-90.
24. Palladini G, Russo P, Milani P, Foli A, Lavatelli F, Nuvolone M, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica. 2013;98(3):433-6.
25. Gertz M, Comenzo R, Falk R, Fermand J, Hazenberg B, Hawkins P, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol. 2005;(79):319-28.
26. Common Terminology for Adverse Events Version 3.0. U.S. Department of Health and Human Services. National Institutes of Health. National Cancer Institute. Published August 9, 2006.
27. Palladini G, Dispenzieri A, Gertz M, Kumar S, Wechalekar A, Hawkins P, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012; 30(36):4541-9.
28. Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman S, Buadi F, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011; 86(1):12-8.
29. Lebovic D, Hoffman J, Levine BM, Hassoun H, Landau H, Goldsmith Y, et al. Predictors of survival in patients with systemic lightchain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol. 2008; 143(3):369-73.
30. Dietrich S, Schonland SO, Benner A, Bochtler T, Kristen AV, Beimler J, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diag-nosed systemic light chain amyloidosis and severe cardiac involvement. Blood. 2010;116(4):522-8.
31. Palladini G, Russo P, Lavatelli F, Nuvolone M, Albertini R, Bosoni T, et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol. 2009; 88(4):347-50.
32. Tapan U, Seldin DC, Finn KT, Fennessey S, Shelton A, Zeldis JB, et al. Increases in Btype natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood. 2010;116(23):5071-72.
33. Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S, et al. Discordance between serum cardiac biomarker and immunoglobulin-free lightchain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol. 2010; 85(10):757-9.
34. Mikhael J, Schuster S, Jimenez-Zepeda V, Bello N, Spong J, Reeder CB, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19): 4391-4.
35. Venner C, Lane T, Foard D, Rannigan L, Gibbs S, Pinney J, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progressionfree survival. Blood. 2012;119(19):4387-90.